XREF

Income statement

Sources: FY2022/FY2023 Annual Reports; FY2025 Appendix 4E (revenue A$21,314,154 vs A$19,859,555; loss A$1,953,345 vs A$5,681,097); FY2026 preliminary final report (revenue A$19,143,411, -10.2%; loss A$432,066, -77.9%; opex A$14.9m, -23.9%). FY2025 opex derived from -23.9%. Discrepancy: FY2026 release states underlying EBITDA +76% to A$4.7m, implying an FY2025 base of ~A$2.67m, while the FY2025 Appendix 4E reported A$2.3m — likely a redefinition of "underlying"; both noted.

Margins and growth (derived)

FY2022 gross margin derived from cost of sales against Xref+marketplace revenue base; treat as approximate. Revenue CAGR FY2022–FY2026: ~0.7% p.a. (derived) — essentially flat over four years.

Commentary. The five-year record shows three phases: (1) FY2021–FY2022 post-COVID hiring boom with record credit sales and a small profit; (2) FY2023–FY2024 investment phase (Engage launch, enterprise platform, capitalised development) with expenses rising 29% in FY2023 and losses peaking at A$5.7m in FY2024 as hiring cooled; (3) FY2025–FY2026 restructure and SaaS migration, cutting opex by ~A$4.7m in FY2026 (wages -27%) and lifting underlying EBITDA margin to ~25% even as revenue fell 10% (migration discounting, legacy churn and weaker hiring). The inflection is cost-led, not revenue-led.

Balance sheet

H1 FY2025 cash A$3.3m (31 Dec 2024). Debt: borrowing facility with Element SaaS Finance LLC (US SaaS lender) outstanding through FY2026, repaid on 28 August 2026 via a new CBA A$6.3m term facility maturing August 2029 plus a A$2.0m overdraft. Negative NTA indicates deferred revenue and debt exceed tangible assets — typical for SaaS but a constraint given small cash.

Cash flow

No dividends or buybacks.

Ratios

ROE, ROA and ROIC are negative/not meaningful given losses and negative NTA. Indicative leverage: CBA term debt A$6.3m vs FY2026 underlying EBITDA A$4.7m ≈ 1.3x gross debt/EBITDA; net debt ~A$4.0m ≈ 0.85x (derived, assuming facility fully drawn and cash A$2.3m). Interest coverage, current ratio and cash conversion cycle not publicly disclosed in sources reviewed.

Guidance: Management expects continued profitable growth and further margin expansion from platform operating leverage; FY2027 priorities are migration completion, upsell, conversion and retention. No numeric guidance.

Bull case

1. At ~3x EV/underlying EBITDA and ~1x ARR, the market prices Xref as distressed despite A$4.7m EBITDA and a refinanced balance sheet.

2. Migration is ~complete (71% New Platform ARR); once legacy churn ends, New Platform growth (+50% in FY2026) should drive Group ARR growth.

3. Strategic value is proven: SEEK offered A$0.218/share (4x current price) in 2024; substantial holders (EPI, Thorney, Tanda) could catalyse a renewed approach.

Bear case

1. Revenue is shrinking (-10.2%) and Group ARR has fallen ~15% since December 2024 — EBITDA gains came from cuts, which are finite.

2. Liquidity is thin (A$2.3m cash, A$6.3m debt); any hiring downturn could pressure covenants.

3. Low barriers to entry and bundling by ATS/screening giants threaten pricing.

Catalysts / monitorables: AGM 23 Nov 2026; H1 FY2027 results (Feb 2027) — Group ARR growth vs decline; legacy ARR run-off; cash generation post-refinance; marketplace/RapidID growth; any M&A approach; substantial-holder movements.

Analyst verdict. Xref is a case study in a pioneering product that never reached the scale its early growth promised. Revenue of A$19.1m in FY2026 is barely above FY2022's A$18.6m, and the company has spent the intervening years investing, restructuring twice and migrating customers from credits to subscriptions. The failed SEEK scheme in February 2025 — at A$0.218, a 61% premium — now looks like a significant missed exit for shareholders, with the stock trading near A$0.05 eighteen months later.

Yet the operating picture today is materially better than the share price suggests. The FY2026 result shows a business that has cut opex by almost a quarter, delivered A$4.7m underlying EBITDA, nearly eliminated statutory losses and secured bank refinancing through 2029 on better terms than its specialist SaaS lender. The New Platform is growing ARR at 50% and now represents 71% of recurring revenue; the drag from legacy and Engage ARR should diminish as migration completes.

The central question is whether Xref can convert a cost-led turnaround into revenue growth. If Group ARR returns to growth in H1 FY2027, the current valuation — around 1x ARR and ~3x EBITDA — is difficult to justify for a profitable vertical SaaS asset with a defensible data archive, and a strategic acquirer (SEEK, a screening major or an HR-platform owner such as a Tanda-aligned party) could reappear. If ARR keeps shrinking, the company risks being a sub-scale, illiquid micro-cap with limited capacity to invest against much larger competitors.

On balance, Xref is a high-risk, deep-value special situation: the downside is cushioned by refinanced debt and positive EBITDA, while the upside depends on revenue re-acceleration or corporate activity. Monitoring Group ARR trajectory is the single most important task for investors over the next two reporting periods.